Coloplast (OTCMKTS: CLPBY) and Smith & Nephew (NYSE:SNN) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings.
This is a summary of recent recommendations and price targets for Coloplast and Smith & Nephew, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Smith & Nephew||1||1||4||0||2.50|
Smith & Nephew has a consensus price target of $45.00, indicating a potential upside of 25.10%. Given Smith & Nephew’s higher probable upside, analysts plainly believe Smith & Nephew is more favorable than Coloplast.
This table compares Coloplast and Smith & Nephew’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Smith & Nephew||N/A||N/A||N/A|
Risk and Volatility
Coloplast has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500. Comparatively, Smith & Nephew has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500.
Institutional and Insider Ownership
0.1% of Coloplast shares are owned by institutional investors. Comparatively, 8.7% of Smith & Nephew shares are owned by institutional investors. 1.0% of Smith & Nephew shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Coloplast and Smith & Nephew’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Coloplast||$2.31 billion||8.35||$564.23 million||N/A||N/A|
|Smith & Nephew||$4.77 billion||3.30||$767.00 million||$1.90||18.93|
Smith & Nephew has higher revenue and earnings than Coloplast.
Coloplast pays an annual dividend of $0.10 per share and has a dividend yield of 1.0%. Smith & Nephew pays an annual dividend of $0.68 per share and has a dividend yield of 1.9%. Smith & Nephew pays out 35.8% of its earnings in the form of a dividend.
Smith & Nephew beats Coloplast on 7 of the 13 factors compared between the two stocks.
Coloplast A/S develops and markets intimate healthcare products and services worldwide. The company operates through three segments: Chronic Care, Urology Care, and Wound & Skin Care. It provides ostomy care products for intestinal dysfunction resulting from disease, accident, and congenital disorder. The company's ostomy care products include colostomy, ileostomy, and urostomy bags under the SenSura brand; and SenSura Mio, a colostomy product with elastic adhesive that fits individual body shapes, as well as ostomy accessories under the Brava brand. It also offers urology care products for people suffering from diseases and symptoms of the urinary system, pelvic floor prolapse, and the male reproductive system, such as urinary incontinence, kidney stones, enlarged prostate, and impotence. The company's disposable surgical devices include prostate catheters and stents used for urological and gynecological applications before, during, and after surgery under the Porgès brand; vaginal slings to restore continence; synthetic mesh products to treat weak pelvic floor; and penile implants for men. In addition, it provides continence care products, such as SpeediCath catheters that offer catherisation for both genders; Peristeen, an anal irrigation system for controlled emptying of the bowels; and Conveen Active urine bags. Further, the company offers wound care products, such as foam dressings under the Biatain brand and hydrocolloid dressing under the Comfeel brand, as well as skin care products, such as disinfectant liquids or creams used to protect and treat the skin and to clean wounds. Additionally, it offers Interdry, a textile placed in a skin fold to absorb moisture for treatment and prevention of skin fold problems, such as fungal infections, damaged skin, or odour nuisance. The company supplies its products to hospitals, institutions, wholesalers, and pharmacies; and directly to users. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.
About Smith & Nephew
Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder. It also provides arthroscopic enabling technologies for healthcare providers comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue. In addition, the company offers trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; robotics-assisted surgery, various products, and technologies to assist in surgical treatment of the ear, nose, and throat; knee implant products for specialized knee replacement procedures; and hip implant products for the reconstruction of hip joints. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration; and advanced wound devices, such as traditional and single-use negative pressure wound therapy and hydrosurgery systems. The company primarily serves the providers of medical and surgical treatments and services. Smith & Nephew plc was founded in 1856 and is headquartered in London, the United Kingdom.
Receive News & Ratings for Coloplast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast and related companies with MarketBeat.com's FREE daily email newsletter.